SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Latigo Biotherapeutics, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

08/11/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons AI Biotechnology LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 3,185,177.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,185,177.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 3,185,177.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 5.0 %
12		Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission (the "SEC") on August 7, 2026.

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons Access Industries Holdings LLC
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,185,177.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,185,177.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 3,185,177.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

11	Percent of class represented by amount in row (9) 5.0 %
12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Access Industries Management, LLC		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 3,185,177.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 3,185,177.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,185,177.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 5.0 %		
12	Type of Reporting Person (See Instructions) OO		

Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Len Blavatnik	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,185,177.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,185,177.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,185,177.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.0 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026.

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Latigo Biotherapeutics, Inc.

(b) Address of issuer's principal executive offices:

1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA 91320

Item 2.

(a) Name of person filing:

AI Biotechnology LLC Access Industries Holdings LLC ("AIH") Access Industries Management, LLC ("AIM") Len Blavatnik

(b) Address or principal business office or, if none, residence:

The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.

Citizenship:

(c) Each of AI Biotechnology, AIH and AIM is a limited liability company organized under the laws of the State of Delaware. Mr. Blavatnik is a citizen of the United States of America.

Title of class of securities:

(d) Common stock, par value $0.0001 per share

CUSIP No.:

(e)

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) See the responses to Item 9 on the attached cover pages.

Percent of class:

(b) See the responses to Item 11 on the attached cover pages. The percentages reported in Item 11 on the attached cover pages are based upon 63,238,030 shares of Common Stock outstanding immediately following the Issuer's initial public offering, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 7, 2026. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See the responses to Item 5 on the attached cover pages.

(ii) Shared power to vote or to direct the vote:

See the responses to Item 6 on the attached cover pages.

(iii) Sole power to dispose or to direct the disposition of:

See the responses to Item 7 on the attached cover pages.

(iv) Shared power to dispose or to direct the disposition of:

See the responses to Item 8 on the attached cover pages. 3,185,177 shares of Common Stock are held directly by AI Biotechnology and may also be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH controls all of the outstanding voting interests in AI Biotechnology. Each of the Reporting Persons (other than AI Biotechnology) and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AI Biotechnology LLC

Signature:	/s/ Alejandro Moreno
Name/Title:	By: Access Industries Management, LLC, its manager; its Executive Vice President, General Counsel/Alejandro Moreno
Date:	08/18/2026

Access Industries Holdings LLC

Signature:	/s/ Alejandro Moreno
Name/Title:	By: Access Industries Management, LLC, its manager; its Executive Vice President, General Counsel/Alejandro Moreno
Date:	08/18/2026

Access Industries Management, LLC

Signature:	/s/ Alejandro Moreno
Name/Title:	Executive Vice President, General Counsel/Alejandro Moreno
Date:	08/18/2026

Len Blavatnik

Signature:	*/s/Alejandro Moreno
Name/Title:	By: Alejandro Moreno/Attorney-in-Fact
Date:	08/18/2026

Comments accompanying signature: * The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.